Potential of Interferon-?? in Solid Tumours
- 1 January 2002
- journal article
- Published by Springer Nature in BioDrugs
- Vol. 16 (5) , 349-372
Abstract
The second part of this review examines the use of recombinant interferon-α (rIFNα) in the following solid tumours: superficial bladder cancer, Kaposi’s sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma and ovarian, breast and cervical malignancies. In superficial bladder cancer, intravesical rIFNα has a promising role as second-line therapy in patients resistant or intolerant to intravesical bacille Calmette-Guérin (BCG). In HIV-associated Kaposi’s sarcoma, rIFNα is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts >200/mm3, no prior opportunistic infections and nonvisceral disease. rIFNα has shown encouraging results when used in combination with retinoids in the chemoprevention of head and neck squamous cell cancers. It is effective in the chemoprevention of hepatocellular cancer in hepatitis C-seropositive patients. In neuroendocrine tumours, including carcinoid tumour, low-dosage (≤3MU) or intermediate-dosage (5 to 10MU) rIFNα is indicated as second-line treatment, either with octreotide or alone in patients resistant to somatostatin analogues. Intracavitary IFNα may be useful in malignant pleural effusions from mesothelioma. Similarly, intraperitoneal IFNα may have a role in the treatment of minimal residual disease in ovarian cancer. In breast cancer, the only possible role for IFNα appears to be intralesional administration for resistant disease. IFNα may have a role as a radiosensitising agent for the treatment of cervical cancer; however, this requires confirmation in randomised trials. On the basis of current evidence, the routine use of rIFNα is not recommended in the therapy of head and neck squamous cell cancers, upper gastrointestinal tract, colorectal and lung cancers, or mesothelioma. Pegylated IFNα (peginterferon-α) is an exciting development that offers theoretical advantages of increased efficacy, reduced toxicity and improved compliance. Further data from randomised studies in solid tumours are needed where rIFNα has activity, such as neuroendocrine tumours, minimal residual disease in ovarian cancer, and cervical cancer. A better understanding of the biological mechanisms that determine response to rIFNα is needed. Studies of IFNα-stimulated gene expression, which are now feasible, should help to identify molecular predictors of response and allow us to target therapy more selectively to patients with solid tumours responsive to IFNα.Keywords
This publication has 290 references indexed in Scilit:
- Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-α-2c in patients with advanced colorectal cancer: final results of a randomised phase III studyEuropean Journal of Cancer, 1999
- Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesotheliomaEuropean Journal of Cancer, 1997
- Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cellsEuropean Journal of Cancer, 1997
- Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: An overview of clinical trialsEuropean Journal of Cancer, 1995
- Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-α2b and folinic acid. The “GISCAD” experienceEuropean Journal of Cancer, 1994
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994
- Double modulation of 5-fluorouracil by high-dose leucovorin and interferon?2b in advanced colorectal cancerJournal of Cancer Research and Clinical Oncology, 1994
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal of Cancer, 1992
- Natural interferon alfa as maintenance therapy for small cell lung cancerEuropean Journal of Cancer, 1992
- A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumourEuropean Journal of Cancer, 1992